ImpediMed Ltd
ASX:IPD
Net Margin
ImpediMed Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
ImpediMed Ltd
ASX:IPD
|
68.8m AUD |
-184%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
230.9B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
194.9B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
155.7B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
145.1B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
108.3B USD |
13%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
54.7B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.8B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.8B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
40.3B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
274.8B CNY |
31%
|
ImpediMed Ltd
Glance View
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on ImpediMed Ltd's most recent financial statements, the company has Net Margin of -183.8%.
You don't have any saved screeners yet